Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavaleukin alfa long-term extension in moderate to severe ulcerative colitis
NL-OMON56326Phase 2Not yet recruiting
- Sponsor
- Amgen
- Start
- Mar 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, double-blind, single-arm trial of efavaleukin alfa in autoimmune colitis, sponsored by Amgen. Primary endpoint: Treatment-emergent adverse events. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
efavaleukin alfa
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON56326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56326.